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Integrated Continuous Biomanufacturing (ICB) provides many important strategic advantages for therapeutic 
protein production through process intensification, simplification and integration. Dramatic reductions in cost of 
goods manufactured can be achieved by pushing perfusion culture towards high productivity at moderate 
perfusion rate and integrating with multi-column capture. We have demonstrated that an in-house chemically 
defined medium designed for high volumetric productivity (VPR) can support clones producing different 
monoclonal antibodies in perfusion bioreactors at cell densities >100 million viable cells/mL and VPR from 4 to  
6 g/L/day. However, for other cell lines tested productivity could not be consistently sustained due to declining 
growth rate at high cell density. It was demonstrated that increased bleed rates could extend the culture duration 
for these clones but only with substantially lower cell density and productivity, and reverting to a less productive 
perfusion medium improved culture longevity to a certain degree.  It was shown that continuous addition of a 
concentrated supplement to this medium could improve productivity to levels comparable to the high-VPR 
medium, but this appeared to be less effective for clones with lower specific productivity.  Some clones 
producing the same biologic were observed to exhibit either sustained or declining growth rate at high cell 
density, indicating clonal variability should be considered as another factor that can affect this growth 
phenotype.  Potential strategies to mitigate declining growth rate in high cell density perfusion culture will be 
discussed and additional case studies on the application of intensified perfusion will be examined. 
 
